In this systematic review and meta‐analysis, treatment with GLP‐1 or dual GIP/GLP‐1 RAs was associated with a significantly reduced risk of papilledema and visual disturbances or blindness, and with a near‐significant reduction in headache risk compared with standard‐of‐care IIH treatment. The gene discussed is GIP; the disease is optic papillitis.